GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Gross Profit

Cambium Bio (ASX:CMB) Gross Profit : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Gross Profit?

Cambium Bio's gross profit for the six months ended in Dec. 2023 was A$0.00 Mil. Cambium Bio's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Cambium Bio's gross profit for the six months ended in Dec. 2023 was A$0.00 Mil. Cambium Bio's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Cambium Bio's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

Cambium Bio had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

During the past 11 years, the highest Gross Margin % of Cambium Bio was 99.45%. The lowest was 49.73%. And the median was 83.23%.


Cambium Bio Gross Profit Historical Data

The historical data trend for Cambium Bio's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Gross Profit Chart

Cambium Bio Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.66 7.96 - - -

Cambium Bio Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cambium Bio's Gross Profit

For the Biotechnology subindustry, Cambium Bio's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cambium Bio's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Gross Profit distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Gross Profit falls into.



Cambium Bio Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Cambium Bio's Gross Profit for the fiscal year that ended in Jun. 2024 is calculated as

Gross Profit (A: Jun. 2024 )=Revenue - Cost of Goods Sold
=0.001 - 0
=0.00

Cambium Bio's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Cambium Bio's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Cambium Bio  (ASX:CMB) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Cambium Bio had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Cambium Bio Gross Profit Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Cambium Bio Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio Headlines

No Headlines